Healthcare / Medical Care FacilitiesTokyo
$850.00
-30.00 (-3.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-30.9M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
21.0x
↑EV/EBITDA
4.1x
↓ROE
5.4%
↑Gross Margin
23.5%
↓Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.9%
FCF CAGR
-32.8%
FCF margin
7.0%
FCF / Net income
2.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.71B · net income $101.9M · FCF $258.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.71B | $3.71B | $2.91B | $3.60B | $6.24B |
| Net Income | $101.9M | $101.9M | $48.0M | $120.0M | $500.1M |
| EBITDA | $177.9M | $177.9M | $117.5M | $234.8M | $788.1M |
| EPS | — | — | 19.06 | 47.63 | 198.42 |
| Gross Margin | 23.5% | 23.5% | 27.5% | 25.1% | 20.3% |
| Operating Margin | 2.6% | 2.6% | 1.8% | 4.8% | 11.5% |
| Net Margin | 2.7% | 2.7% | 1.7% | 3.3% | 8.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.65 | 0.63 | 0.70 |
| Current Ratio | 1.87 | 1.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $258.5M | $258.5M | $-89.0M | $-30.9M | $853.7M |
| Returns | |||||
| ROE | 5.4% | 5.4% | 2.7% | 7.0% | 31.1% |
| Valuation | |||||
| P/E | 21.00 | 21.00 | 46.90 | 16.90 | 5.34 |
| EV/EBITDA | 4.10 | 4.10 | 9.62 | 3.62 | 1.83 |
| P/B | 1.13 | 1.13 | 1.25 | 1.18 | 1.66 |
| Growth & Yield | |||||
| Revenue Growth | 27.7% | 27.7% | -19.2% | -42.3% | — |
| EPS Growth | — | — | -60.0% | -76.0% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.2%
Start / end P/E
n/dx → n/dx
EPS bridge
19.06 → n/d
Residual
-18.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.